Lifeline Biotechnologies Stock Annual Yield
| LLBO Stock | USD 0.0001 0.0003 75.00% |
Lifeline Biotechnologies fundamentals help investors to digest information that contributes to Lifeline Biotechnologies' financial success or failures. It also enables traders to predict the movement of Lifeline Pink Sheet. The fundamental analysis module provides a way to measure Lifeline Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lifeline Biotechnologies pink sheet.
Lifeline |
Lifeline Biotechnologies Company Annual Yield Analysis
Lifeline Biotechnologies' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, Lifeline Biotechnologies has an Annual Yield of 0.0%. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Medical Devices (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Funds Screener Now
Funds ScreenerFind actively-traded funds from around the world traded on over 30 global exchanges |
| All Next | Launch Module |
Lifeline Fundamentals
| Current Valuation | 4.25 M | |||
| Net Income | (574.27 K) | |||
| Cash And Equivalents | 603.32 K | |||
| Total Debt | 448.07 K | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 8.42 X | |||
| Book Value Per Share | 0 X | |||
| Beta | -1.86 | |||
| Market Capitalization | 10.99 M | |||
| Total Asset | 6.72 M | |||
| Z Score | 14.4 | |||
| Net Asset | 6.72 M |
About Lifeline Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lifeline Biotechnologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lifeline Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lifeline Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Lifeline Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lifeline Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lifeline Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving against Lifeline Pink Sheet
| 0.57 | BSX | Boston Scientific Corp | PairCorr |
| 0.48 | EW | Edwards Lifesciences Corp | PairCorr |
| 0.47 | DXCM | DexCom Inc | PairCorr |
| 0.45 | SYK | Stryker | PairCorr |
| 0.43 | BRK-A | Berkshire Hathaway | PairCorr |
The ability to find closely correlated positions to Lifeline Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lifeline Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lifeline Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lifeline Biotechnologies to buy it.
The correlation of Lifeline Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lifeline Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lifeline Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lifeline Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Lifeline Pink Sheet
Lifeline Biotechnologies financial ratios help investors to determine whether Lifeline Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lifeline with respect to the benefits of owning Lifeline Biotechnologies security.